Investor Intel - SZLS
StageZeros early cancer detection tests and telehealth platform are growing fast . MATTHEW BOHLSEN | DECEMBER 12, 2019. Cancer is a terrible and common disease. According to the WHO: One in 5 men and one in 6 women worldwide develop cancer during their lifetime; and one in 8 men and one in 11 women die from the disease. Experts all agree early detection is the key. I know from personal experience in my family that two lives have already been saved from detecting cancers early.StageZero Life Sciences Ltd. (TSX: SZLS) is a Canada-based company focused on developing and commercializing molecular diagnostic tests for early detection of cancer. StageZero has developed the Sentinel Principle platform technology which determines bio-markers from whole blood.StageZeros diagnostic testsAristotle is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Aristotle platform has been validated on 10,000 patients and used to develop the first liquid biopsy for colorectal cancer.Chairman and CEO of StageZero Life Sciences, James Howard-Tripp, stated: There is significant interest in being able to screen easily and routinely for multiple cancers, and our tests meet this need. Other StageZero diagnostic tests for early cancer detection include ColonSentry, BreastSentry, Prostate Heath Index, and Early CDT-Lung. More at: https://investorintel.com/sectors/biotech-healthcare/biotech-intel/stagezeros-early-cancer-detection-tests-and-telehealth-platform-are-growing-fast/